Loading company
Axogen, Inc.
AXGN · Nasdaq · ·
Next earnings: November 4, 2026
$42.43-2.1%Sep 29 close
- 1M
- -14.9%
- 6M
- +26.4%
- 1Y
- +137.4%
- 5Y
- +157.2%
AXGN · Nasdaq · ·
Next earnings: November 4, 2026
$42.43-2.1%Sep 29 close
Axogen, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $69.7M | $56.7M | +23.06% |
| Profit | -$1.5M | $579K | -361.83% |
| Profit per share | -$0.03 | $0.01 | -400.00% |
| Free Cash Flow | $6.3M | $7M | -9.70% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s product portfolio includes Avance ® (acellular nerve allograft-arwx), Avance ® Nerve Graft, Axoguard Nerve Connector ® , Axoguard Nerve Protector ® , Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap ® , and Avive+ Soft Tissue Matrix™.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Axogen, Inc.’s Item 2.02 8-K filed July 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Axogen, Inc. has no earnings call transcript available.